JP2004537252A - 前立腺癌の治療及び診断のための組成物及び方法 - Google Patents

前立腺癌の治療及び診断のための組成物及び方法 Download PDF

Info

Publication number
JP2004537252A
JP2004537252A JP2001537498A JP2001537498A JP2004537252A JP 2004537252 A JP2004537252 A JP 2004537252A JP 2001537498 A JP2001537498 A JP 2001537498A JP 2001537498 A JP2001537498 A JP 2001537498A JP 2004537252 A JP2004537252 A JP 2004537252A
Authority
JP
Japan
Prior art keywords
seq
prostate
polynucleotide
cells
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001537498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537252A5 (de
Inventor
シュー，ジャンチュン
シー． ディロン，デイビン
エル． ミッチャム，ジェニファー
エル． ハーロッカー，スーザン
ジャン，ユーキウ
ジー． リード，スティーブン
ディー． カロス，マイケル
ダブリュ． レター，マーク
エー． ストーク，ジョン
エイチ． デイ，クレイグ
エー．ダブリュ． スケイキー，ヤサー
ワン，アイジュン
Original Assignee
コリクサ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/439,313 external-priority patent/US6329505B1/en
Application filed by コリクサ コーポレイション filed Critical コリクサ コーポレイション
Publication of JP2004537252A publication Critical patent/JP2004537252A/ja
Publication of JP2004537252A5 publication Critical patent/JP2004537252A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001537498A 1999-11-12 2000-11-09 前立腺癌の治療及び診断のための組成物及び方法 Pending JP2004537252A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/439,313 US6329505B1 (en) 1997-02-25 1999-11-12 Compositions and methods for therapy and diagnosis of prostate cancer
US44368699A 1999-11-18 1999-11-18
PCT/US2000/030904 WO2001034802A2 (en) 1999-11-12 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009017430A Division JP2009142284A (ja) 1999-11-12 2009-01-29 前立腺癌の治療および診断のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2004537252A true JP2004537252A (ja) 2004-12-16
JP2004537252A5 JP2004537252A5 (de) 2008-05-22

Family

ID=27032000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001537498A Pending JP2004537252A (ja) 1999-11-12 2000-11-09 前立腺癌の治療及び診断のための組成物及び方法

Country Status (5)

Country Link
EP (1) EP1230364A2 (de)
JP (1) JP2004537252A (de)
AU (1) AU1656501A (de)
CA (1) CA2391369A1 (de)
WO (1) WO2001034802A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504808A (ja) * 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
ATE321857T1 (de) 1999-09-29 2006-04-15 Diagnocure Inc Pca3 mrna in gutartigen und bösartigen prostatageweben
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
CA2386854A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Methods of using a mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of heterologous proteins
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
BR0107643A (pt) * 2000-01-14 2003-06-10 Corixa Corp Composições e processos para a terapia e diagnóstico de c ncer de próstata
US20020009455A1 (en) * 2000-04-27 2002-01-24 Ted Lau DNA encoding a novel PROST 03 polypeptide
CA2413959C (en) 2000-06-20 2015-07-07 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP1328549A4 (de) * 2000-10-03 2004-10-06 Human Genome Sciences Inc Für die humane prostata spezifischer g-protein-rezeptor hpraj70
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
DE60313163T2 (de) * 2002-06-11 2008-01-03 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzungen
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
EP1636379A2 (de) * 2003-06-26 2006-03-22 Exonhit Therapeutics S.A. Prostata-spezifische gene und deren verwendung als ziele für die therapie und diagnose von prostatakrebs
BRPI0418766B8 (pt) 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CA3055132A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1998050567A1 (en) * 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO1999067384A2 (en) * 1998-06-22 1999-12-29 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
KR19990087802A (ko) * 1996-03-15 1999-12-27 길리스 스티브 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법
EP1870466A3 (de) * 1998-07-14 2008-03-19 Corixa Corporation Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Prostatakrebs
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1998050567A1 (en) * 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO1999067384A2 (en) * 1998-06-22 1999-12-29 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504808A (ja) * 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法

Also Published As

Publication number Publication date
WO2001034802A9 (en) 2002-08-08
WO2001034802A2 (en) 2001-05-17
AU1656501A (en) 2001-06-06
CA2391369A1 (en) 2001-05-17
EP1230364A2 (de) 2002-08-14
WO2001034802A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
JP2004537252A (ja) 前立腺癌の治療及び診断のための組成物及び方法
US7033827B2 (en) Prostate-specific polynucleotide compositions
US6800746B2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7939646B2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7074898B2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
EP1870466A2 (de) Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Prostatakrebs
EP1988097A1 (de) Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Prostatakrebs
RU2234942C2 (ru) Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
AU3447401A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CA2403909A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020192763A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020193296A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020081680A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7048931B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20060269532A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
JP2009142284A (ja) 前立腺癌の治療および診断のための組成物および方法
US6894146B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020051977A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CA2613125A1 (en) Compositions and methods for therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20060815

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329